ArticleAdvanced materials (Deerfield Beach, Fla.)2026
A Xerotic Skin-Compatible Neuromotor Electrode Interface for Non-Invasive Muscle Weakness Evaluation in Dermatomyositis.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ZBP1 contributes to IFN-β-induced PANoptosis-related skeletal muscle cell injury in dermatomyositis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Dermatomyositis creates a clinical demand for non-invasive, quantitative muscle weakness assessment, which can be achieved by decomposing neuromotor information from surface electromyography (sEMG). However, the absence of a stable electrode interface compatible with pathologically xerotic skin has hindered this approach. Here, we develop a conformable neuromotor electrode interface that overcomes this via molecular engineering, exhibiting an ultrasoft modulus (∼ 2.13 kPa), low impedance (∼ 0.9 kΩ at 1 kHz), and stable electrical retention over 7 days. This interface enables the acquisition of high-fidelity sEMG from dermatomyositis patients with low baseline noise (< 2 µV root mean square) and high inter-channel signal correlation, allowing robust decomposition of neuromotor biomarkers including motor unit count, action potential amplitude, and firing rate. Clinically, our multi-biomarker quantification strategy shows strong agreement with gold standard assessments. Moreover, our approach can detect subtle interpatient variations like early recruitment patterns, enabling personalized treatment beyond the clinical gold standard. This work establishes a transformative platform for precise muscle weakness evaluation, overcoming the limitations of needle electromyography and subjective clinical scales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.